NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Scribe Therapeutics Inc. (SCTX) Stock Analysis

Scribe Therapeutics Inc. (SCTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SCTX

$19.30

−$0.51 (−2.57%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SCTX with… →

SCTX Key Statistics

As of Oct 21, 2026
Trading
Open
$19.90
Previous Close
$19.81
Day's Range
19.00–21.00
52-Week Range
13.50–39.60
Volume
485.26K
Valuation
Market Cap
$365.38M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
10.97
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.84
Financials (FY)
Revenue (FY)
$51.17M+86.68%
Net Income (FY)
−$21.81M
Profit marginThe share of revenue left as profit after all costs and taxes.
−97.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
18.93M
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
350.60K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Scribe Therapeutics Inc. (SCTX) has a market capitalization of $365.38M.

In fiscal 2025, SCTX reported revenue of $51.17M.

SCTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$51.17M−$21.81M−42.6%
2024$27.41M−$47.79M−174.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$51.17M—−$26.07M−$21.81M−42.6%
2024$27.41M—−$42.83M−$47.79M−174.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SCTX Valuation vs Biotechnology Median

Median of 608 stocks
MetricSCTXBiotechnology medianvs median
P/S ratio10.9713.3017% below
Profit margin−97.00%−38.31%58.7 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Scribe Therapeutics Inc. (SCTX) carries a market capitalisation of $365.38M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 82.

SCTX last closed at $19.30 on October 21, 2026. That is −$0.51 (−2.57%) against the previous close. The 52-week range on file runs from $13.50 to $39.60. The latest close sits 42.96% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $51.17M. That is +86.68% against the prior fiscal year, when revenue was $27.41M. The same year closed with a net loss of $21.81M. The reported profit margin is −97%. That is 58.7 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −3.84.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 10.97 times revenue. On price-to-sales that is 17.5% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Growth & Income

No dividend is on file for SCTX.

2026 is still running; the total return is −10.85% year to date.

Peer Comparison

Scribe Therapeutics Inc. (SCTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Scribe Therapeutics Inc. SCTX $365.38M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Scribe Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Scribe Therapeutics Inc.

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.

Visit website →